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Abstract 
Topical treatment is the cornerstone for the management of mild to moderate psoriasis. Despite efforts in drug 
development, patient's satisfaction with the available topical treatments is limited. A strategy to improve safety, 
efficacy and comfort of topical treatment provides the development of new drug delivery and drug carrier systems. 
This review provides an overview of recent advances in this field with a focus on psoriasis. Laser-assisted drug 
delivery, foam formulations, nanoparticles, ethosomes, and niomes are considered. Hopefully, these new 
developments will improve topical drug therapy and patient satisfaction. 
 
 
 
 
 
 
 
 
 
 
Introduction 
 
Easy accessibility of skin is a major factor for 
topical treatment. Topical drug delivery is depended 
on skin barrier properties, physicochemical properties 
of drug and vehicle, and interaction between drug and 
its vehicle with the skin layers. Penetration into intact 
skin is usually limited to hydrophilic substances 
smaller than 500 Da. This explains why highly 
hydrophilic or highly lipophilic compounds or such 
compounds with a higher molecular weight are much 
less suitable for conventional topical drug therapy [1]. 
Psoriasis is a chronic inflammatory skin 
disease affecting about 2% of the world population 
that harms various dimensions of quality of life of 
patients [2]. Topical drug therapy is the cornerstone in 
the treatment of mild to moderate psoriasis. It offers a 
direct targeting of affected skin by avoiding systemic 
adverse events. However, patient satisfaction with 
available treatments remains modest [3]. 
There are three major pathways by which 
drug release into the skin and into the systemic 
circulation by topical application have to be 
considered: (a) percutaneous absorption - the 
passage of topically applied materials into the skin, (b) 
percutaneous penetration - the passage of material 
from the stratum corneum surface through the skin to 
the systemic circulation, and (c) permeation – the 
passage of material through a skin by diffusion or by 
pores.  
Percutaneous penetration is measured by in 
vitro skin models such as skin disks, human or animal 
tissue samples in special skin chambers. 
Percutaneous penetration measurements are 
performed in vivo in animal models or humans since 
they are dependent on blood circulation. Drug 
concentrations are usually measured by high-
performance liquid chromatography (HPLC) or mass 
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spectrometry [4]. Proton nuclear magnetic resonance 
(
1
H NMR) spectroscopy allows the characterisation of 
the most represented proton-containing low-
molecular-mass compounds in a biological sample 
and their representation in a spectrum [5]. 
In recent years, several technologies have 
been developed to enhance the efficacy and safety of 
topical drug therapy. Furthermore, new drug carriers 
offer the opportunity to introduce new molecules into 
topical psoriasis therapy. For these purposes, 
vesicular drug delivery systems including niosomes, 
proniosomes, liposomes and transferosomes, 
nonvesicular drug delivery systems such as foams, 
gels, and nanoparticles have been developed [6]. 
Hopefully, by using these new technologies, better 
patient satisfaction with topical treatment could be 
achieved. 
 
 
Ablative Fractional Lasers 
 
Fractional ablative lasers can enhance the 
permeation of topical drugs into the skin through 
microscopic ablation zones (MAZs) of precise 
dimensions. At this moment, the skin barrier can be 
negotiated, and drug delivery markedly improved [7].  
Several studies investigated topical 
methotrexate. Methotrexate is a folic acid analogue. 
The mechanism of action is the inhibition of 5-
aminoimidazole-4-carboxamide ribonucleotide 
transformylase, thus increasing intracellular and 
extracellular adenosine which has anti-inflammatory 
activity. Methotrexate has been used for a long time in 
the systemic treatment of both psoriasis and psoriasis 
arthritis. In contrast to its use in oncology, 
methotrexate is used just once a week in low dosages 
(usually 7.5-25 mg) orally, subcutaneously or 
intravenously in both indications [8]. Systemic 
treatment, however, is limited by possible 
methotrexate toxicities [9]. 
A systematic in vitro study with a low-power 
2,940 nm ablative fractional erbium YAG laser 
investigated the correlation between laser parameters 
and tissue. Deeper MAZ depth increased the 
concentration of methotrexate in the deeper tissue 
layer. The biodistribution of the drug was surprisingly 
not compromised by coagulation zones of various 
thickness around MAZ. The ratio of skin deposition 
versus transdermal permeation was constant, not 
depending on the MAZ depth. Methotrexate 
distributed radially from the MAZ. Saturation of the 
skin occurred after 7 hours at a ten-fold concentration 
compared to intact skin [10]. 
The same technique can be applied to the 
treatment of nail psoriasis [11]. 
In a clinical trial using nanoparticulated 
methotrexate in jojoba oil-based microemulsion, 
fractional erbium YAG laser resulted in a faster clinical 
response compared to intact skin, i.e. 3 weeks vs 8 
weeks [12]. 
 
 
Foams 
 
Foams are colloids composed of two or three 
distinct phases: hydrophilic liquid continuous phase 
with a foaming agent, throughout which a gaseous 
dispersion phase is distributed, and sometimes a third 
hydrophobic dispersed phase. Pharmaceutical aerosol 
foams commonly exhibit three transition states: liquid 
in the can, propellant/aerosol as it leaves the can and 
foam on the skin of the patient [13].  
A fixed combination of calipotriol and 
betametasone dipropionate is on the market and 
found to superior to betamethasone ointment [14]. 
Betamethasone dipropionate in micronised particles 
can be easily suspended homogeneously. 
Calcipotriol, on the other hand, is a greater challenge 
and needs to be dissolved in a carefully selected 
vehicle component to ensure even distribution. The 
product contains an emollient vehicle base, with 
calcipotriol and betamethasone dissolved in a mixture 
of volatile propellants, butane and dimethyl ether. 
Dimethyl ether also acts as a solvent that enhances 
the solubility of the active ingredients allowing them to 
dissolve completely. It has been demonstrated that 
this anti-psoriatic foam formulation is more effective at 
week 12 than systemic methotrexate or acitretin, and 
it is more effective at week 16 as systemic apremilast 
measured by the PASI75 response [15].  
 
 
Nanofibres 
 
Curcumin is a herbal substance with anti-
inflammatory activities, that is of interest also in topical 
psoriasis therapy [16]. Cellulose nanofiber (CNF) is a 
biocompatible biomaterial with film-forming properties 
and excellent mechanical properties. Fibres of a 
diameter of approximately 500 nm were embedded in 
a composition containing shea butter and Capmul 
MCM EP and loaded with curcumin (liquid@CNF). 
They employed a variety of analytical methods 
including scanning and transmission electron 
microscopy, Fourier transform infrared spectroscopy, 
also known as FTIR analysis. The FTIR analysis 
method uses infrared light to scan test samples and 
observe chemical properties. X-ray photoelectron 
spectroscopy was used to analyse the surface 
chemistry of the curcumin preparation. Besides, 
atomic force microscopy was used to measure the 
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local properties of curcumin-CSF. In a mouse model 
with imiquimod-induced psoriasis-like dermatitis, 
deposition of curcumin was increased 2-fold 
compared with films missing the lipid component. 
Curcumin-CNF improved dermatitis in vivo including a 
reduction of pro-inflammatory cytokines in a range 
close to commercially available topical corticosteroids. 
Furthermore, the films had a skin hydration effect [17].  
 
 
Nanoparticles and Nano Emulsions 
 
Another option to overcome skin barrier is the 
use of nanoparticles, especially for hydrophilic 
compounds. The most commonly used nanoparticles 
for topical drug delivery are polymeric nanoparticles, 
nano-emulsions, liposomes and solid lipid 
nanoparticles, metal nanoparticles, and dendrimers. 
Nanoparticles are used to enhance the solubility of 
highly hydrophobic drugs. They provide a sustained 
and controlled release of drugs while increasing their 
stability. Nanoparticles are capable of delivering 
higher concentrations of drugs to target areas. 
Nanoparticles can accumulate in hair follicles and 
thereby overcome the skin barrier [18].  
Curcumin-loaded nanoparticles (NPs) made 
of poly (lactic-co-glycolic acid) with a mean particle 
size of 50 nm and 150 nm. In vitro, these NPs exerted 
a stronger anti-proliferative activity of human HaCaT 
keratinocytes than curcumin alone. Psoriatic skin 
samples were used for in vitro penetration studies. 
Curcumin-loaded NPs delivered more curcumin into 
the skin than curcumin hydrogel. Curcumin-loaded 
NPs was investigated in vivo in the imiquimod-induced 
mouse model versus tacrolimus cream. Clinical 
symptoms, histology and inflammatory cytokines 
improved most with curcumin-loaded NPs with 50 nm 
NPs reaching the most pronounced effects [19]. 
An amphiphilic polymer, RRR-α-tocopheryl 
succinate-grafted-ε-polylysine conjugate (VES-g-ε-
PLL), was synthesised and self-assembled into skin 
penetrating polymeric NPs with a hydrodynamic 
diameter of only 24.4 nm. In these NPs curcumin 
could effectively be encapsulated with a drug loading 
capacity of 3.49% and an encapsulating efficiency of 
78.45%. Silk fibroin was used as a hydrogel-based 
matrix to enhance further topical delivery of curcumin-
NPs, which resulted in a slower release. In vivo 
studies on imiquimod-induced psoriasis-like dermatitis 
in mice, curcumin-NPs-silk fibroin gel demonstrated a 
high skin-permeating capability and a stronger anti-
inflammatory activity. This was investigated by 
inhibitory effects on the expression of pro-
inflammatory cytokines such as tumour necrosis 
factor-alpha (TNFa), nuclear factor-κB and interleukin-
6) [20]. 
Bacterial cellulose (BC) represents an 
interesting biocompatible nanomaterial. BC can be 
easily manipulated to improve its properties and/or 
functionalities resulting in several BC-based 
nanocomposites such as BC/collagen, BC/gelatin, 
BC/fibroin, BC/chitosan. Bacterial 
cellulose/carboxymethylcellulose (BC / CMC) 
biocomposite nanofibers can also serve as drug 
carriers. This was investigated using methotrexate, a 
conventional systemic antipsoriatic drug with anti-
folate activity. Biocomposites loaded with 
methotrexate may be used as an alternative for the 
topical treatment of psoriasis. There was a decrease 
in the elastic modulus as the degree of substitution of 
CMC increased. Intermediate substitute CMC grade 
led to a slightly decreased MTX release rate, 
suggesting that the degree of substitution of CMC is a 
key factor to modulate the biocomposite properties 
[21]. 
Spherical methotrexate-loaded chitin nanogel 
(MCNG) with a particle size of 196 nm was formulated 
for topical use in psoriasis. Exposure of HaCaT 
keratinocytes and THP-1 cells to MCNG showed a 
significant level of cellular toxicity. MCNGs inhibited 
COX-2 and LOX-5 enzymes expressed in THP-1 
cells. Skin permeation studies revealed an increased 
transdermal flux of methotrexate from MCNG in 
comparison with methotrexate solution treated 
samples. Furthermore, it could be shown that MCNG 
exerted anti-psoriatic efficacy on an imiquimod-
induced mouse model of psoriasis. No dermal and 
systemic toxicities were reported [22]. 
Pentoxifylline (PTX) is an anti-inflammatory 
activity compound and exerts inhibitory activity against 
TNFa, one of the major proinflammatory cytokines 
involved in psoriasis. Therefore, it is of potential 
interest in topical psoriasis therapy — colloidal 
nanostructured lipid carriers (NLCs) with a size of less 
than 200 nm. PTX was loaded and encapsulated to 
the extent of 10% and 90% in the NLCs. In vitro 
studies suggested high retention of PTX in the skin 
(84%). In vivo, imiquimod-induced psoriasis in the 
mouse model was employed. PTX-loaded NCLs 
demonstrated a significant improvement of histological 
changes in the affected epidermis [23].  
In contrast to PTX, topical corticosteroids are 
established drugs in psoriasis therapy. They are the 
cornerstone of topical outpatient treatment worldwide. 
Mometasone furoate-loaded NLCs with a droplet size 
of approximately 160 nm, a zeta potential-0.086 mV 
and entrapment efficiency of 60.0 % were transformed 
into a hydrogel using Carbopol 940 to optimise 
viscosity for topical use. Drug permeation studies 
showed prolonged drug release as compared to 
commercial mometasone formulation. The 
mometasone skin concentration was 2.5-fold higher 
than commercial corticosteroids. In vivo studies in 
imiquimod induced skin inflammation in Wistar rats 
demonstrated the absence of parakeratosis in 
mometasone-loaded NLC treated lesions [24]. 
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Nanogels are water-soluble cross-linked 
polymer networks with nanometer-size dimensions. 
They can be designed to incorporate different types of 
anti-psoriatic compounds and are promising carrier 
systems for topical drug delivery. Gels produced with 
macromolecules and fibres can be classified as 
polymers with molecules attached to the fibres 
throughout the gel resulting in a polymer (chemical 
gel) or supramolecular gels (physical gels), in which 
smaller molecules are attached van der Waals 
interactions, hydrogen bonds or coulombic forces [25]. 
While chemical gels are robust materials, physical 
gels are more suitable for drug delivery. These gels 
are also softer. While most physical gels are made by 
polymeric subunits, low‐molecular‐weight gelators 
(LMWGs) are smaller molecules that self‐assemble to 
form fibres. Such gels have qualities that made them 
interesting for drug delivery, such as 
thermoreversibility and degradability [26].  
Bis‐imidazolium (1⋅2 Br) salts are cationic 
surfactants that could form micelles and deliver 
anionic drugs. The electrostatic attraction between the 
positively charged surfactant and the negatively 
charged drug is responsible for a slow but sustained 
release of the drug [27]. Triamcinolone acetonide and 
betamethasone 17‐valerate are commonly used 
topical corticosteroid for inflammatory skin disorders 
such as psoriasis. The 1⋅2 Br carrier material 
permitted a high level of drug release and did not limit 
permeation of the drug into human skin as measured 
by Franz cells. Gels derived from 1⋅2 Br released up 
to three times more triamcinolone or betamethasone 
than two commercial products, which served as 
controls. Also, the speed of drug release was ten 
times faster if they were incorporated in gel 1⋅2 Br. 
Permeation studies using Franz cells show that gel 
1⋅2 Br promotes the entry of the drug through the skin 
four times more rapidly than the commercial 
formulations. The gel also promotes retention of the 
drug in the skin two times (betamethasone) and 20-
fold (triamcinolone) more than the commercial 
formulations. In conclusion, 1⋅2 Br carrier material 
ensures a faster action and higher bioavailability to 
the pharmacological target [28].  
Further investigations demonstrated that 
several other possible compounds for topical psoriasis 
therapy could also be included and stabilised in 
nanostructures supramolecular gels such as 
methotrexate or tacrolimus [29].  
PUVA-therapy – 8-methoxy psoralen (8MOP) 
plus ultraviolet A irradiation – is an established 
treatment for psoriasis, vitiligo and cutaneous T-cell 
lymphoma amongst other dermatoses [30]. 
8MOP has been incorporated into a 
nanoemulsion (NE) that showed a mean droplet 
diameter of 24.98 ± 0.49 nm, polydispersity index of 
0.091 ± 0.23, pH values of 6.54 ± 0.06, the refractive 
index of 1.3525 ± 0.0001, and apparent viscosity of 
51.15 ± 3.66 mPa at 20°C. The formulation was 
characterised by ex vivo permeation study using 
porcine skin with fluorescence HPLC and 
transmission electron microscopy, to determine the 
amount of drug retained in stratum corneum, viable 
epidermis, and dermis. Ex vivo permeation revealed 
that 8.5% of the applied 8MOP dose permeated 
through the biological membranes, with a flux of 
1.35 μg cm
-2
 h
-1
. The drug retention in viable epidermis 
and dermis was twice as high as normal cream with 
10.15 ± 1.36 µg cm
-2 
compared to stratum corneum 
with 1.95 ± 0.71 µg cm
-2
, respectively [31].  
Since NE may have a relatively low viscosity, 
hydrogel-thickened NEs using chitosan have been 
prepared to improve topical applicability. The size of 
chitosan molecules influences drug release [32]. 
Cignolin (syn. dithranol or anthralin) is the 
most potent topical drug in psoriasis therapy with the 
longest remission times [33]. However, skin irritation 
and staining hamper its broader use. Microspongues 
as delivery systems for cignolin may overcome these 
problems. In one study, microsponges were 
composed of poly (amido) amine dendrimers, 
ethylcellulose, polyvinyl alcohol, dichloromethane, 
sodium metabisulphate, and distilled water. In vitro 
studies demonstrated that such a formulation could 
prevent autooxidation of cignolin. Microsponge gel of 
dithranol may provide further advantages of reduced 
side effects, increased elegance, enhanced 
formulation flexibility, and modified drug release [34]. 
Cignolin has also been used with NLCs for 
better application and efficacy. Cignolin-loaded NLCs 
were prepared by hot-melt homogenization with 
particle size < 300 nm, polydispersity index (PDI) < 
0.3 and percentage entrapment efficiency of ∼100%. 
The NLCs were loaded into a gel and evaluated for 
drug release, spreadability, rheological behaviour, and 
staining. Anti-psoriatic efficacy was evaluated in the 
imiquimod-induced psoriatic plaque model in 
comparison with conventional 1.15% w/w cignolin 
ointment. Topical application of cignolin-loaded NLC 
gel reduced the PASI score. There was a significant 
reduction in IL-17, 22, 23 and TNFa as measured by 
enzyme-linked immunosorbent assays [35]. 
Cyclosporine A (CsA) is a calcineurin inhibitor 
which acts on T-cells and is an effective systemic 
treatment for psoriasis. However, systemic 
administration of CsA can cause dose-dependent 
toxic effects, which may be circumvented by topical 
drug delivery. Topical use, however, is hindered by its 
high molecular weight of 1,202 Da [36]. 
Recently a topical liposomal gel containing 
CsA loaded cationic liposomal nanocarriers has been 
developed. Optimised liposomal carriers prepared by 
the ethanol injection method were loaded with CsA 
and applied in a gel formulation on imiquimod-induced 
plaque model. Thereby, clinical symptoms could be 
improved, and key pro-inflammatory cytokines for 
psoriasis such as tumour necrosis factor-α, IL-17, and 
IL-22 were reduced [37].  
Review Article 
_______________________________________________________________________________________________________________________________ 
 
_______________________________________________________________________________________________________________________________ 
3022                                                                                                                                                                                              https://www.id-press.eu/mjms/index 
 
A CsA-loaded microemulsions using oleic 
acid as oil phase, either Tween®80 or a soluble 
derivative of vitamin E (TPGS) as surfactants and 
either Transcutol®, propylene glycol or 1,3 
propanediol as co-surfactants. Several Tween®80-
based and 4 TPGS-based formulations were tested ex 
vivo, loaded with 6 mg/g CsA and applied ex-vivo on 
porcine skin for 22 h. A 3- or 6-fold higher cutaneous 
accumulation compared with CsA in propylene glycol 
could be obtained by a low-viscosity Tween®80-
based microemulsion (9.78 ± 3.86 µg cm
-2
) and with a 
high viscosity TPGS-based microemulsion 
(18.3 ± 5.69 µg cm
-2
), respectively. The uptake of CsA 
by porcine skin was noted as early as two hours after 
application [38]. 
Another study investigated CsA-loaded 
polymeric micelles using the biodegradable and 
biocompatible MPEG-dihexPLA diblock copolymer. 
These polymeric micelles deliver CsA without 
penetrating the skin. They increased the aqueous 
solubility of CsA by 518-fold. Supra-therapeutic 
amounts of CsA were delivered to human skin (1.4 ± 
0.6 μg cm
-2
) after application of the formulation with 
1.67 mg/ml CsA and 5 mg/ml copolymer for the only 
1h without transdermal permeation. The micelles were 
preferentially deposited between corneocytes and in 
between the clusters of corneocytes [39].  
Tacrolimus is a specific calcineurin inhibitor 
approved or atopic dermatitis and with moderate 
antipsoriatic activity for intertriginous psoriasis [40]. It 
suffers from poor cutaneous bioavailability when 
administered topically as protopic ointment. Therefore, 
polymeric micelles using methoxy-poly (ethylene 
glycol)-dihexyl substituted polylactide (MPEG-
dihexPLA) diblock copolymer loaded with 0.1% 
tacrolimus was investigated in vitro. Delivery 
experiments using human skin resulted in significantly 
greater tacrolimus deposition compared to protopic 
0.1% ointment, i.e. 1.50 ± 0.59 versus 0.47 ± 0.20 μg 
cm
-2
). The increase in cutaneous drug concentrations 
was due to improved drug load of stratum corneum, 
viable epidermis, and upper dermis, while the 
copolymer was unable to penetrate the stratum 
corneum. Preferential deposition of tacrolimus-loaded 
micelles into the hair follicle was also documented 
[41]. 
Another study investigated a hybrid system 
based on nicotinamide (NIC) and nanoparticles (NPs) 
encapsulating tacrolimus to improve percutaneous 
drug delivery. NIC increased both the solubility and 
permeability of tacrolimus. NIC demonstrated self-
assembly with amphiphilic hyaluronic acid-cholesterol 
conjugates. Thee NPs showed a higher encapsulation 
efficiency of 79.2% ± 4.2%, and the combination of 
NPs with NIC exhibited a significant synergistic effect 
on tacrolimus absorption within the skin (2.39 ± 0.53 
μg cm
-2
) and penetration through the skin (13.38 ± 
2.26 μg cm
-2
) as measured by confocal laser scanning 
microscopy. The cellular uptake of tacrolimus in 
HaCaT cells was also improved by NPs [42]. 
One trial investigated the applicability of NIC-
based hybrid systems with chitosan instead of 
hyaluronic acid on tacrolimus efficacy in an animal 
model of atopic dermatitis (AD). AD-like skin lesions 
were induced by 1-chloro-2, 4-dinitrobenzene (DNCB) 
in BALB/c mice. In vitro and in vivo skin permeation 
studies demonstrated that this NIC-chitosan-NPs 
system significantly enhanced tacrolimus cutaneous 
permeation and penetration compared to commercial 
tacrolimus ointment. The treatment efficacy on clinical 
symptoms, histological analysis, and molecular 
biology of the AD-mice demonstrated that NIC-
chitosan-NPs were more potent than the commercial 
ointment while using only one-third of their dosage 
[43]. The anti-TNFa fusion protein etanercept 
(molecular weight 150 kDa) is an effective drug in the 
systemic treatment of moderate to severe psoriasis. 
Due to the high molecular weight, the compound 
cannot penetrate human skin [44].  
Recently, etanercept was successfully and 
stable encapsulated in thermoresponsive nanogels 
(tNG). Topical application of etanercept-loaded tNGs 
to human skin equivalents, prepared from primary 
human keratinocytes and fibroblasts and treated with 
TNFa, or tape striped human skin resulted in 
inefficient drug delivery throughout the stratum 
corneum and into the viable epidermis. Effective 
etanercept delivery was depended on temperature 
triggered release following topical application. Anti-
inflammatory activity on TNFa, intercellular adhesion 
molecule 1, and thymic stromal lymphopoietin was 
measured by immunochemistry, enzyme-linked 
immunoassays, and Western blots. It was shown that 
the formulation was non-toxic for monocyte-derived 
Langerhans cells [45]. 
In another study, two different tNGs were 
synthesized, i.e. tNG_dPG_tPG-a combination of 
dendritic polyglycerol with poly (glycidyl methyl ether-
co-ethyl glycidyl ether) (p(GME-co-EGE)) and 
tNG_dPG_pNIPAM with poly(N-isopropylacrylamide). 
These tNGs were capable of incorporating high 
amounts of the corticosteroid dexamethasone and 
tacrolimus. Cellular uptake and intracellular 
localisation were investigated in cell cultures of normal 
human keratinocytes and HaCaT cells. Neither 
cytotoxic nor genotoxic effects were noted. There was 
no induction of reactive oxygen species in 
keratinocytes. tNGs with a thermally triggered release 
at 35°C seem to be optimal for topical application on 
human skin [46].  
 
 
Ethosomes 
 
Ethosomes are flexible nanovesicles 
composed of multiple, concentric layers of flexible 
phospholipid bylayers, with 20 to 45% of ethanol, 
glycol and water. They are used for dermal and 
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transdermal delivery of molecules since they can 
penetrate the stratum corneum [47]. 
However, percutaneous absorption and 
penetration of lipophilic 8MOP in intact skin are poor. 
After the development of microemulsions about 20 
years ago, more recently nanocarriers were 
investigated for improved drug supply of 8MOP. In 
vitro skin permeation demonstrated a permeability of 
psoralen-loaded ethosomes superior to that of 
liposomes. With psoralen-loaded ethosomes, 
transdermal flux and skin deposition could be 
increased 3.50 and 2.15 times compared to psoralen-
loaded liposomes [48]. 
One trial used spherical and multilamellar 
ethosomes incorporated into Carbopol® 934 gel. They 
were characterized for drug content, rheological 
behaviour, texture profile, in vitro release, ex vivo skin 
permeation and retention, skin photosensitization and 
histopathological examination. Ethosomal 
formulations showed significant skin permeation and 
accumulation in the epidermal and dermal layers as 
demonstrated by fluorescence microscopy study using 
123
rhodamine while phototoxicity was not enhanced 
[49]. 
 
 
Niosomes 
 
Niosomes represent non-ionic surfactant-
based vesicles formed mostly by non-ionic surfactant 
and cholesterol. They can entrap lipophilic drugs into 
vesicular bilayer membranes and hydrophilic drugs. 
Niosomes are osmotically active [50]. 
Acitretin is a vitamin-A analogue with 
antipsoriatic and anti-inflammatory activities. Systemic 
acitretin therapy warrants a close laboratory 
monitoring to prevent severe adverse events. 
Niosomes of approximately 370 nm were loaded with 
acitretin. Acitretin nanosized niosomal gel offered an 
enhanced ex vivo permeation profile drug deposition 
in the viable skin layers compared with acitretin gel. 
Acitretin-loaded nano-niosomes demonstrated an 
increased antiproliferative activity in HaCaT cell 
culture. Topical application of acitretin nano-niosomal 
gel to a mouse tail model achieved a significantly 
higher amount of orthokeratosis, drug activity, and 
reduction in epidermal thickness compared with 
controls. The formulation was characterised by 
improved tolerability and much less skin irritation [51]. 
Niosome technology has also been 
investigated for PUVA therapy with 8MOP. 8MOP 
niosomes were prepared by the thin-film hydration 
method along with cholesterol demonstrated a high 
entrapment efficiency (83-90%) with vesicle diameters 
between 111.1 and 198.8 nm. Physical stability over 6 
months at different temperatures was good. Niosome 
formulations were incorporated in 5% sodium carboxy 
methylcellulose-hydrogel matrix which showed a more 
retarded 8MOP release compared to niosomal 
vesicles. The skin penetration of the niosomes was 
studies in vivo by confocal laser scanning microscopy 
using 
123
rhodamine-loaded niosomal hydrogels 
compared to plain 
123
rhodamine hydrogel. In vitro drug 
permeation and deposition studies with rat skin 
demonstrated improved penetration and accumulation 
of 8MOP after 8h [52]. 
Proniosomes are liquid crystalline compact 
niosome hybrids which upon hydration form 
niosomes. They support physical stability such as 
leaking, fusion, aggregation and provide convenience 
in dosing, distribution, transportation and storage. 
Therefore, proniosomes seem to be superior to 
conventional niosomes [53]. 
A non-ionic surfactant based proniosomal gel 
(PNG) was developed to improve topical delivery of 
tazarotene – a retinoid for psoriasis. The PNG was 
had a vesicle size of 3.26 μm. Different formulations 
were investigated for drug release through cellulose 
membrane and rat skin, which showed a prolonged 
release of entrapped tazarotene. The formulations 
varied in drug permeation and retention in vitro. The 
male Albino NMRI mice tail model was used for in vivo 
studies. Span 60 based PNG formulations were able 
to increase drug accumulation in skin and reduce 
parakeratosis in the horny layer [54]. 
 
 
Conclusions 
 
Topical drug delivery is a field of recent 
research with great clinical implications. In contrast to 
the development of targeted systemic treatments and 
biologics, improved topical drug delivery is focused on 
the great majority of psoriasis patients with mild to 
moderate disease. Various anti-inflammatory drugs 
and herbal compounds are under investigation. 
Hopefully, a number these topical treatments become 
available for the dermatologic practice. 
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